Lv, Fang <br/><br/>
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis.  [electronic resource] 

 -  Bone  01 2020 
 - 115121 p.  digital 
<br/><br/> Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review 
<br/><br/><label>ISSN: </label>1873-2763 
<br/><br/><label>Standard No.: </label>10.1016/j.bone.2019.115121  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--adverse effects<br/>Cardiovascular Diseases--drug therapy<br/>Denosumab--adverse effects<br/>Female<br/>Humans<br/>Osteoporosis--drug therapy